Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Predict branded drug patent expiration
  • Identify first generic entrants

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

Details for Patent: 5,192,741

« Back to Dashboard

Summary for Patent: 5,192,741

Title: Sustained and controlled release of water insoluble polypeptides
Abstract:There is disclosed a pharaceutical composition for sustained and controlled release of drug over an extended period of time comprising a polylactide, a copolymer of lactic and glycolic acid, a mixture of such polymers and a water-insoluble peptide which, when placed in an aqueous physiologically-type environment releases the peptide in continuous manner for a period of at least one week, and with an initial release for the first twenty-four hours of not more than 30% of the total amount released. There is thus provided the control of the release pattern and in general a decrease of the initial burst effect.
Inventor(s): Orsolini; Piero (Martigny, CH), Mauvernay; Rolland-Yves (Lausanne, CH), Deghenghi; Romano (Lausanne, CH)
Assignee: Debiopharm S.A. (Lausanne, CH)
Application Number:07/247,060
Patent Claim Types:
see list of patent claims
Composition; Process; Dosage form; Delivery; Formulation;

No matches for this query

Foreign Priority and PCT Information for Patent: 5,192,741

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom8722134Sep 21, 1987

International Patent Family for Patent: 5,192,741

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria397035► Subscribe
AustriaA223488► Subscribe
Australia2232688► Subscribe
Australia611944► Subscribe
Belgium1001685► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.